Iwakiri Publications

• Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd-Chiari syndrome in Japan.Furuichi Y, Kage M, Ohta M, Ohfuji S, Sasaki H, Hidaka H, Yoshida H, Kanto T, Kusano H, Akahoshi T, Obara K, Hashizume M, Kuniyoshi Y, Kawaguchi T, Okubo H, Ishikawa T, Hirooka M, Iwakiri Y, Nio M, Tanaka A. Hepatol Res. 2024 Nov; 2024 Oct 4. PMID: 39364631.
• Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation.Yanagisawa H, Maeda H, Noguchi I, Tanaka M, Wada N, Nagasaki T, Kobayashi K, Kanazawa G, Taguchi K, Chuang VTG, Sakai H, Nakashima H, Kinoshita M, Kitagishi H, Iwakiri Y, Sasaki Y, Tanaka Y, Otagiri M, Watanabe H, Maruyama T. Redox Biol. 2024 Oct; 2024 Aug 17. PMID: 39163766.
• Unlocking the role of liver sinusoidal endothelial cells: Key players in liver fibrosis: Editorial on "Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis".Iwakiri Y. Clin Mol Hepatol. 2024 Oct; 2024 May 10. PMID: 38726502.
• Nogo-B inhibition facilitates cholesterol metabolism to reduce hypercholesterolemia.Xue C, Zeng P, Gong K, Li Q, Feng Z, Wang M, Chen S, Yang Y, Li J, Zhang S, Yin Z, Liang Y, Yan T, Yu M, Feng K, Zhao D, Yang X, Zhang X, Ma L, Iwakiri Y, Chen L, Tang X, Chen Y, Chen H, Duan Y. Cell Rep. 2024 Sep 24; 2024 Sep 3. PMID: 39235944.
• Publisher Correction: Intestinal Nogo-B reduces GLP1 levels by binding to proglucagon on the endoplasmic reticulum to inhibit PCSK1 cleavage.Gong K, Xue C, Feng Z, Pan R, Wang M, Chen S, Chen Y, Guan Y, Dai L, Zhang S, Jiang L, Li L, Wang B, Yin Z, Ma L, Iwakiri Y, Tang J, Liao C, Chen H, Duan Y. Nat Commun. 2024 Sep 10; 2024 Sep 10. PMID: 39256382.
• Intestinal Nogo-B reduces GLP1 levels by binding to proglucagon on the endoplasmic reticulum to inhibit PCSK1 cleavage.Gong K, Xue C, Feng Z, Pan R, Wang M, Chen S, Chen Y, Guan Y, Dai L, Zhang S, Jiang L, Li L, Wang B, Yin Z, Ma L, Iwakiri Y, Tang J, Liao C, Chen H, Duan Y. Nat Commun. 2024 Aug 10; 2024 Aug 10. PMID: 39122737.
• Interleukin-7-based identification of liver lymphatic endothelial cells reveals their unique structural features.Yang Y, Jeong J, Su T, Lai S, Zhang P, Garcia-Milian R, Graham M, Liu X, McConnell MJ, Utsumi T, Pereira J, Iwakiri Y. JHEP Rep. 2024 Jul; 2024 Mar 18. PMID: 38966234.
• Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice.Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC. Cancer Cell. 2024 Jun 10; 2024 May 30. PMID: 38821059.
• Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis.Chen Y, Li Q, Zhao S, Sun L, Yin Z, Wang X, Li X, Iwakiri Y, Han J, Duan Y. Biochem Pharmacol. 2023 Dec; 2023 Nov 17. PMID: 37979703.
• Lymphatic drainage dysfunction is related to clinically significant portal hypertension.Ma R, Iwakiri Y. Hepatol Int. 2023 Dec; 2023 Sep 24. PMID: 37743398.
• The Sympathetic Nervous System Promotes Hepatic Lymphangiogenesis, which Is Protective Against Liver Fibrosis.Tanaka M, Jeong J, Thomas C, Zhang X, Zhang P, Saruwatari J, Kondo R, McConnell MJ, Utsumi T, Iwakiri Y. Am J Pathol. 2023 Dec; 2023 Sep 4. PMID: 37673329.
• An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.Jeong J, Tanaka M, Yang Y, Arefyev N, DiRito J, Tietjen G, Zhang X, McConnell MJ, Utsumi T, Iwakiri Y. Am J Physiol Gastrointest Liver Physiol. 2023 Nov 1; 2023 Aug 22. PMID: 37605828.
• S-nitrosylation of EMMPRIN influences the migration of HSCs and MMP activity in liver fibrosis.Zhu X, Tang Z, Li W, Li X, Iwakiri Y, Liu F. Acta Biochim Biophys Sin (Shanghai). 2023 Oct 25. PMID: 37700592.
• What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.Kim 金雄來 WR, Iwakiri 岩切泰子 Y, Lok 駱淑芳 ASF. Hepatology. 2023 Oct 1; 2023 Apr 19. PMID: 37070237.
• Protocol for enrichment, purification, and cytocentrifugation of mouse liver endothelial cells.Chowdhury S, Fried KD, Iwakiri Y, Brancale J, Vilarinho S. STAR Protoc. 2023 Sep 15; 2023 Jul 28. PMID: 37515764.
• Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis.Yasuda K, Maeda H, Kinoshita R, Minayoshi Y, Mizuta Y, Nakamura Y, Imoto S, Nishi K, Yamasaki K, Sakuragi M, Nakamura T, Ikeda-Imafuku M, Iwao Y, Ishima Y, Ishida T, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. ACS Nano. 2023 Sep 12; 2023 Aug 14. PMID: 37579503.
• Endotheliopathy of liver sinusoidal endothelial cells in liver disease.Kondo R, Iwakiri Y, Kage M, Yano H. Pathol Int. 2023 Sep; 2023 Aug 17. PMID: 37589433.
• The evolving role of liver sinusoidal endothelial cells in liver health and disease.McConnell MJ, Kostallari E, Ibrahim SH, Iwakiri Y. Hepatology. 2023 Aug 1; 2023 Jan 3. PMID: 36626620.
• Lymphatics in the liver for translational science.Iwakiri Y. Clin Liver Dis (Hoboken). 2023 Apr; 2023 Feb 24. PMID: 37936952.
• Overexpression of NgBR inhibits high-fat diet-induced atherosclerosis in ApoE-deficiency mice.Gong K, Wang M, Wang D, Gao Y, Ma L, Yang X, Zhu X, Chen S, Zhang M, Li H, Chen Y, Hu W, Miao QR, Iwakiri Y, Liao C, Duan Y, Han J. Hepatol Commun. 2023 Apr 1; 2023 Mar 30. PMID: 36996002.
• Portal Hypertension in Alcohol-Associated Hepatitis.McConnell MJ, Iwakiri Y. Curr Hepatol Rep. 2023; 2023 Apr 5. PMID: 37214274.
• Hepatic lymphatic vascular system in health and disease.Jeong J, Tanaka M, Iwakiri Y. J Hepatol. 2022 Jul; 2022 Feb 11. PMID: 35157960.
• Inhibition of high-fat diet-induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms.Wang X, Yang Y, Zhao D, Zhang S, Chen Y, Chen Y, Feng K, Li X, Han J, Iwakiri Y, Duan Y, Yang X. J Biol Chem. 2022 Feb; 2022 Jan 5. PMID: 34998825.
• Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis.McConnell MJ, Kondo R, Kawaguchi N, Iwakiri Y. Hepatol Commun. 2022 Feb; 2021 Nov 10. PMID: 34658172.
• Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH.Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. J Control Release. 2022 Jan; 2021 Nov 29. PMID: 34856227.
• Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases.Kondo R, Kawaguchi N, McConnell MJ, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Sun Z, Utsumi T, Strazzabosco M, Iwakiri Y. Hepatol Res. 2021 Sep; 2021 Aug 2. PMID: 34260803.
• Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee AI, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. J Hepatol. 2021 Sep; 2021 May 13. PMID: 33991637.
• Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.Iwakiri Y, Trebicka J. JHEP Rep. 2021 Aug; 2021 Jun 4. PMID: 34337369.
• Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.Yang Y, Sangwung P, Kondo R, Jung Y, McConnell MJ, Jeong J, Utsumi T, Sessa WC, Iwakiri Y. J Hepatol. 2021 Aug; 2021 Mar 3. PMID: 33675874.
• Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats.Hsu SJ, Zhang C, Jeong J, Lee SI, McConnell M, Utsumi T, Iwakiri Y. Gastroenterology. 2021 Mar; 2020 Nov 20. PMID: 33227282.
• Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis.Su T, Yang Y, Lai S, Jeong J, Jung Y, McConnell M, Utsumi T, Iwakiri Y. Cell Mol Gastroenterol Hepatol. 2021; 2020 Dec 16. PMID: 33340713.
• Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis.Jeong J, Iwakiri Y. Cell Mol Gastroenterol Hepatol. 2021; 2020 Nov 18. PMID: 33220266.
• Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.Zhang S, Guo F, Yu M, Yang X, Yao Z, Li Q, Wei Z, Feng K, Zeng P, Zhao D, Li X, Zhu Y, Miao QR, Iwakiri Y, Chen Y, Han J, Duan Y. J Hepatol. 2020 Dec; 2020 Jul 29. PMID: 32738448.
• The lymphatic system in alcohol-associated liver disease.Kondo R, Iwakiri Y. Clin Mol Hepatol. 2020 Oct; 2020 Sep 21. PMID: 32951411.
• Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.Su T, Iwakiri Y. Hepatology. 2020 Jul. PMID: 32060947.
• O-GlcNAc transferase suppresses necroptosis and liver fibrosis.Zhang B, Li MD, Yin R, Liu Y, Yang Y, Mitchell-Richards KA, Nam JH, Li R, Wang L, Iwakiri Y, Chung D, Robert ME, Ehrlich BE, Bennett AM, Yu J, Nathanson MH, Yang X. JCI Insight. 2019 Nov 1; 2019 Nov 1. PMID: 31672932.
• Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation.Zhao P, Han SN, Arumugam S, Yousaf MN, Qin Y, Jiang JX, Torok NJ, Chen Y, Mankash MS, Liu J, Li J, Iwakiri Y, Ouyang X. Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1; 2019 Aug 14. PMID: 31411894.
• Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver.Cui J, Piotrowski-Daspit AS, Zhang J, Shao M, Bracaglia LG, Utsumi T, Seo YE, DiRito J, Song E, Wu C, Inada A, Tietjen GT, Pober JS, Iwakiri Y, Saltzman WM. J Control Release. 2019 Jun 28; 2019 May 1. PMID: 31054286.
• Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats.Saruwatari J, Dong C, Utsumi T, Tanaka M, McConnell M, Iwakiri Y. Sci Rep. 2018 Dec 20; 2018 Dec 20. PMID: 30573742.
• Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Drug Deliv. 2018 Nov. PMID: 29688069.
• Lymphatics in the liver.Tanaka M, Iwakiri Y. Curr Opin Immunol. 2018 Aug; 2018 May 14. PMID: 29772409.
• Is miR-21 a potent target for liver fibrosis?Lai S, Iwakiri Y. Hepatology. 2018 Jun; 2018 Apr 19. PMID: 29315674.
• Biology of portal hypertension.McConnell M, Iwakiri Y. Hepatol Int. 2018 Feb; 2017 Oct 26. PMID: 29075990.
• The portal hypertension syndrome: etiology, classification, relevance, and animal models.Bosch J, Iwakiri Y. Hepatol Int. 2018 Feb; 2017 Oct 24. PMID: 29064029.
• Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model.Maxfield MW, Stacy MR, Kurobe H, Tara S, Yi T, Cleary MA, Zhuang ZW, Rodriguez-Davalos MI, Emre SH, Iwakiri Y, Shinoka T, Breuer CK. Regen Med. 2017 Dec; 2017 Dec 7. PMID: 29215317.
• Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, Davies N, Sharma V, Iwakiri Y, Jalan R. J Hepatol. 2017 Nov. PMID: 28893453.
• Reply.Park JK, Iwakiri Y. Hepatology. 2017 Nov; 2017 Sep 29. PMID: 28745830.
• Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis.Shao M, Tian T, Zhu X, Ming Y, Iwakiri Y, Ye S, Ye Q. Oncotarget. 2017 Sep 12; 2017 Aug 2. PMID: 29029524.
• Reply.Iwakiri Y. Hepatology. 2017 Jun; 2017 Apr 28. PMID: 28195342.
• Alcohol and calcium make a potent cocktail.Iwakiri Y, Nathanson MH. J Physiol. 2017 May 15; 2017 Apr 18. PMID: 28295353.
• An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization.Park JK, Shao M, Kim MY, Baik SK, Cho MY, Utsumi T, Satoh A, Ouyang X, Chung C, Iwakiri Y. Hepatology. 2017 May; 2017 Mar 22. PMID: 28090670.
• The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis.Tanaka M, Iwakiri Y. Cell Mol Gastroenterol Hepatol. 2016 Nov; 2016 Sep 14. PMID: 28105461.
• The lymphatic system: A new frontier in hepatology.Iwakiri Y. Hepatology. 2016 Sep; 2016 Jun 23. PMID: 27228259.
• Cellular distribution of injected PLGA-nanoparticles in the liver.Park JK, Utsumi T, Seo YE, Deng Y, Satoh A, Saltzman WM, Iwakiri Y. Nanomedicine. 2016 Jul; 2016 Mar 4. PMID: 26961463.
• Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase.Iwakiri Y. Clin Mol Hepatol. 2015 Dec; 2015 Dec 24. PMID: 26770919.
• Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver.Protiva P, Gong J, Sreekumar B, Torres R, Zhang X, Belinsky GS, Cornwell M, Crawford SE, Iwakiri Y, Chung C. Cell Mol Gastroenterol Hepatol. 2015 Sep 1; 2015 Jul 4. PMID: 26473164.
• Nitric oxide in liver diseases.Iwakiri Y, Kim MY. Trends Pharmacol Sci. 2015 Aug; 2015 May 28. PMID: 26027855.
• Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a.Wang S, Song K, Srivastava R, Dong C, Go GW, Li N, Iwakiri Y, Mani A. FASEB J. 2015 Aug; 2015 Apr 27. PMID: 25917329.
• Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?Kim MY, Iwakiri Y. Hepatol Int. 2015 Jul; 2015 Jan 25. PMID: 25788189.
• Development of small diameter nanofiber tissue engineered arterial grafts.Kurobe H, Maxfield MW, Tara S, Rocco KA, Bagi PS, Yi T, Udelsman B, Zhuang ZW, Cleary M, Iwakiri Y, Breuer CK, Shinoka T. PLoS One. 2015; 2015 Apr 1. PMID: 25830942.
• Hepatic congestion leads to fibrosis: findings in a newly developed murine model.Hidaka H, Iwakiri Y. Hepatology. 2015 Feb; 2015 Jan 5. PMID: 25283276.
• Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed Fel Z, Davies N, Sharma V, Iwakiri Y, Jalan R. J Hepatol. 2015 Feb; 2014 Aug 23. PMID: 25152204.
• Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.Iwakiri Y, Shah V, Rockey DC. J Hepatol. 2014 Oct; 2014 Jun 6. PMID: 24911462.
• Pathophysiology of portal hypertension.Iwakiri Y. Clin Liver Dis. 2014 May; 2014 Feb 25. PMID: 24679494.
• Pigment epithelium-derived factor (PEDF) suppresses IL-1β-mediated c-Jun N-terminal kinase (JNK) activation to improve hepatocyte insulin signaling.Gattu AK, Birkenfeld AL, Iwakiri Y, Jay S, Saltzman M, Doll J, Protiva P, Samuel VT, Crawford SE, Chung C. Endocrinology. 2014 Apr; 2014 Jan 23. PMID: 24456163.
• Reticulon 4 is necessary for endoplasmic reticulum tubulation, STIM1-Orai1 coupling, and store-operated calcium entry.Jozsef L, Tashiro K, Kuo A, Park EJ, Skoura A, Albinsson S, Rivera-Molina F, Harrison KD, Iwakiri Y, Toomre D, Sessa WC. J Biol Chem. 2014 Mar 28; 2014 Feb 20. PMID: 24558039.
• eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases.Di Lorenzo A, Lin MI, Murata T, Landskroner-Eiger S, Schleicher M, Kothiya M, Iwakiri Y, Yu J, Huang PL, Sessa WC. J Cell Sci. 2013 Dec 15; 2013 Sep 17. PMID: 24046447.
• Determination of mesenchymal stem cell fate by pigment epithelium-derived factor (PEDF) results in increased adiposity and reduced bone mineral content.Gattu AK, Swenson ES, Iwakiri Y, Samuel VT, Troiano N, Berry R, Church CD, Rodeheffer MS, Carpenter TO, Chung C. FASEB J. 2013 Nov; 2013 Jul 25. PMID: 23887690.
• Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity.Bryniarski K, Ptak W, Jayakumar A, Püllmann K, Caplan MJ, Chairoungdua A, Lu J, Adams BD, Sikora E, Nazimek K, Marquez S, Kleinstein SH, Sangwung P, Iwakiri Y, Delgato E, Redegeld F, Blokhuis BR, Wojcikowski J, Daniel AW, Groot Kormelink T, Askenase PW. J Allergy Clin Immunol. 2013 Jul; 2013 May 31. PMID: 23727037.
• The lymphatic vascular system in liver diseases: its role in ascites formation.Chung C, Iwakiri Y. Clin Mol Hepatol. 2013 Jun; 2013 Jun 27. PMID: 23837133.
• Reticulon 4B (Nogo-B) facilitates hepatocyte proliferation and liver regeneration in mice.Gao L, Utsumi T, Tashiro K, Liu B, Zhang D, Swenson ES, Iwakiri Y. Hepatology. 2013 May; 2013 Mar 19. PMID: 23299899.
• Absence of Nogo-B (reticulon 4B) facilitates hepatic stellate cell apoptosis and diminishes hepatic fibrosis in mice.Tashiro K, Satoh A, Utsumi T, Chung C, Iwakiri Y. Am J Pathol. 2013 Mar; 2013 Jan 9. PMID: 23313137.
• Activated hepatic stellate cells: negative regulators of hepatocyte proliferation in liver diseases.Chung C, Iwakiri Y. Hepatology. 2012 Jul. PMID: 22876366.
• Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure.Huang HC, Haq O, Utsumi T, Sethasine S, Abraldes JG, Groszmann RJ, Iwakiri Y. J Cell Mol Med. 2012 May. PMID: 21801303.
• A role of miR-33 for cell cycle progression and cell proliferation.Iwakiri Y. Cell Cycle. 2012 Mar 15; 2012 Mar 15. PMID: 22395363.
• Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.Iwakiri Y. Liver Int. 2012 Feb; 2011 Jul 5. PMID: 21745318.
• Proteomic identification of S-nitrosylated Golgi proteins: new insights into endothelial cell regulation by eNOS-derived NO.Sangwung P, Greco TM, Wang Y, Ischiropoulos H, Sessa WC, Iwakiri Y. PLoS One. 2012; 2012 Feb 21. PMID: 22363674.
• Pigment epithelium-derived factor regulates early pancreatic fibrotic responses and suppresses the profibrotic cytokine thrombospondin-1.Schmitz JC, Protiva P, Gattu AK, Utsumi T, Iwakiri Y, Neto AG, Quinn M, Cornwell ML, Fitchev P, Lugea A, Crawford SE, Chung C. Am J Pathol. 2011 Dec; 2011 Sep 28. PMID: 21964188.
• S-nitrosylation of proteins: a new insight into endothelial cell function regulated by eNOS-derived NO.Iwakiri Y. Nitric Oxide. 2011 Aug 1; 2011 Apr 30. PMID: 21554971.
• Reticulon 4B (Nogo-B) is a novel regulator of hepatic fibrosis.Zhang D, Utsumi T, Huang HC, Gao L, Sangwung P, Chung C, Shibao K, Okamoto K, Yamaguchi K, Groszmann RJ, Jozsef L, Hao Z, Sessa WC, Iwakiri Y. Hepatology. 2011 Apr. PMID: 21480333.
• The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma.Shibao K, Fiedler MJ, Nagata J, Minagawa N, Hirata K, Nakayama Y, Iwakiri Y, Nathanson MH, Yamaguchi K. Cell Calcium. 2010 Dec; 2010 Nov 13. PMID: 21075448.
• Vascular biology and pathobiology of the liver: Report of a single-topic symposium.Iwakiri Y, Grisham M, Shah V. Hepatology. 2008 May. PMID: 18393322.
• Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease.Fernández-Hernando C, Ackah E, Yu J, Suárez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, Birnbaum MJ, Sessa WC. Cell Metab. 2007 Dec. PMID: 18054314.
• The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.Iwakiri Y. J Clin Gastroenterol. 2007 Nov-Dec. PMID: 17975478.
• Decreased intrahepatic response to alpha(1)-adrenergic agonists in lipopolysaccharide-treated rats is located in the sinusoidal area and depends on Kupffer cell function.Lee CH, Loureiro-Silva MR, Abraldes JG, Iwakiri Y, Haq O, Groszmann RJ. J Gastroenterol Hepatol. 2007 Jun; 2007 May 13. PMID: 17498219.
• Vascular endothelial dysfunction in cirrhosis.Iwakiri Y, Groszmann RJ. J Hepatol. 2007 May; 2007 Mar 5. PMID: 17391799.
• Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats.Kwon SY, Groszmann RJ, Iwakiri Y. Hepatol Res. 2007 Jan. PMID: 17300699.
• Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking.Iwakiri Y, Satoh A, Chatterjee S, Toomre DK, Chalouni CM, Fulton D, Groszmann RJ, Shah VH, Sessa WC. Proc Natl Acad Sci U S A. 2006 Dec 26; 2006 Dec 14. PMID: 17170139.
• Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state.Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Am J Physiol Gastrointest Liver Physiol. 2006 May. PMID: 16603731.
• Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers.Loureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. J Hepatol. 2006 May; 2006 Feb 28. PMID: 16545481.
• The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.Iwakiri Y, Groszmann RJ. Hepatology. 2006 Feb. PMID: 16447289.
• Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis.Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. J Clin Invest. 2005 Aug. PMID: 16075056.
• Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release.Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ, Iwakiri Y, Sessa WC. J Biol Chem. 2004 Jul 16; 2004 May 10. PMID: 15136572.
• A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. J Hepatol. 2003 Dec. PMID: 14642609.
• Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats.Tsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Gastroenterology. 2003 Nov. PMID: 14598261.
• Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice.Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC. Cancer Cell. 2003 Jul. PMID: 12892711.
• Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension.Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Am J Physiol Gastrointest Liver Physiol. 2002 Nov. PMID: 12381520.
• Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension.Iwakiri Y, Tsai MH, McCabe TJ, Gratton JP, Fulton D, Groszmann RJ, Sessa WC. Am J Physiol Heart Circ Physiol. 2002 Jun. PMID: 12003815.